HALEOS LABS quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	72.9	82.5	−11.6%
EBITDA	9.1	11.7	−22.1%
EBITDA margin	12.5%	14.2%	−1.7 pts
Profit before tax	3.4	7.0	−51.0%
Net profit	1.8	4.4	−58.0%
EPS	₹8.75	₹13.75	−36.4%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	72.9	75.1	94.8	81.4	82.5	89.1	84.6	78.5	92.5	90.0	72.1	69.3	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	0.5	2.0	0.2	0.4	1.0	2.3	0.1	2.0	0.4	2.4	0.6	0.3
	73.4	77.2	95.0	81.8	83.5	91.5	84.7	80.5	93.0	92.4	72.6	69.6
	40.1	35.9	44.7	39.8	28.4	32.7	39.4	35.0	42.7	33.5	39.2	35.7
	−13.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	0.0	−5.0	−1.1	−8.8	6.7	6.6	−3.8	0.8	0.6	10.3	−7.9	−3.5
	17.5	16.2	16.7	16.2	16.3	16.5	14.6	14.1	14.4	12.7	12.6	12.3
	1.9	1.4	1.5	1.6	1.9	2.0	2.1	2.1	2.4	2.8	2.3	2.8
	4.2	3.8	3.9	3.9	3.8	3.8	3.8	3.8	3.7	3.8	3.7	3.7
	19.8	23.9	20.4	20.6	19.4	25.8	21.6	20.0	18.6	22.1	18.9	16.9
	70.0	76.2	86.2	73.3	76.5	87.5	77.7	75.8	82.3	85.3	68.8	67.9
	9.1	4.2	14.0	13.6	11.7	7.4	12.8	8.6	16.3	11.4	9.3	7.9
	4.9	0.3	10.1	9.7	7.9	3.6	9.0	4.8	12.6	7.6	5.6	4.1
Profit
	3.4	0.9	8.8	8.5	7.0	3.9	6.9	4.7	10.6	7.1	3.8	1.7
	3.4	0.9	8.8	8.5	7.0	3.9	6.9	4.7	10.6	7.1	3.8	1.7
	1.6	−1.0	2.0	2.0	2.4	1.0	2.3	2.4	3.1	0.8	1.5	1.4
	−0.0	1.6	0.1	0.1	0.2	−0.6	−0.2	−1.0	0.4	−0.1	−1.8	0.7
	1.6	0.6	2.1	2.1	2.6	0.4	2.1	1.4	3.5	0.6	−0.3	2.1
	1.8	0.3	6.6	6.4	4.4	3.5	4.9	3.3	7.1	6.5	4.1	−0.4
	1.8	0.3	6.6	6.4	4.4	3.5	4.9	3.3	7.1	6.5	4.1	−0.4
	0.0	0.0	0.0	0.0	0.0	0.5	−0.1	−0.1	−0.1	−0.5	0.0	0.0
	1.9	0.4	6.7	6.5	4.4	4.0	4.7	3.2	7.0	6.0	4.1	−0.4
	2.6	0.4	6.6	6.1	4.2	3.0	5.5	4.7	7.0	5.9	4.3	0.7
	−0.8	−0.1	0.0	0.3	0.2	0.5	−0.6	−1.4	0.1	0.6	−0.2	−1.1
Per share
	₹8.75	₹1.44	₹21.89	₹20.19	₹13.75	₹9.83	₹18.08	₹15.46	₹23.15	₹19.53	₹14.24	₹2.20
	₹8.75	₹1.44	₹21.89	₹20.19	₹13.75	₹9.83	₹18.08	₹15.46	₹23.15	₹19.53	₹14.24	₹2.20
Other comprehensive income — detail
	0.0	0.0	0.0	0.0	0.0	0.5	—	—	—	—	—	—
	−0.1	−0.1	−0.1	−0.1	−0.0	−0.8	—	—	—	—	—	—
	—	—	—	—	—	—	0.2	0.2	0.2	0.7	−0.0	−0.0
	0.0	0.0	0.0	0.0	0.0	0.2	—	—	—	—	—	—
	—	—	—	—	—	—	−0.1	−0.1	−0.1	−0.2	0.0	0.0
	2.7	0.5	6.6	6.1	4.2	3.5	5.3	4.5	6.9	5.4	4.3	0.7
	−0.8	−0.1	0.0	0.3	0.2	0.6	−0.6	−1.4	0.1	0.6	−0.2	−1.1
Per share — as-filed variants
	₹8.75	₹1.44	₹21.89	₹20.19	₹13.75	₹9.83	₹18.08	₹15.46	₹23.15	₹19.53	₹14.24	₹2.20
	₹8.75	₹1.44	₹21.89	₹20.19	₹13.75	₹9.83	₹18.08	₹15.46	₹23.15	₹19.53	₹14.24	₹2.20
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	46.5	44.3	51.2	50.3	47.4	49.7	49.0	42.7	49.2	46.2	40.8	37.0
	63.7%	58.9%	54.0%	61.9%	57.4%	55.8%	57.9%	54.4%	53.2%	51.3%	56.6%	53.4%
Adjusted (ex-exceptional items) — derived
	3.4	0.9	8.8	8.5	7.0	3.9	6.9	4.7	10.6	7.1	3.8	1.7
	1.8	0.3	6.6	6.4	4.4	3.5	4.9	3.3	7.1	6.5	4.1	−0.4
	₹8.75	₹1.44	₹21.89	₹20.19	₹13.75	₹9.83	₹18.08	₹15.46	₹23.15	₹19.53	₹14.24	₹2.20

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

HALEOSLABS₹1,450.60

HALEOS LABS LIMITED

· Pharma & Health

Annual Quarterly₹ CrorePeersALBERTDAVD VALIANTLAB MEDICO MEDICAMEQ ZIMLAB AAREYDRUGS NECLIFE ANUHPHRMcap ₹439 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	69.3	72.1	90.0	92.5	78.5	84.6	89.1	82.5	81.4	94.8	75.1	72.9
Other Income	0.3	0.6	2.4	0.4	2.0	0.1	2.3	1.0	0.4	0.2	2.0	0.5
Total Income	69.6	72.6	92.4	93.0	80.5	84.7	91.5	83.5	81.8	95.0	77.2	73.4
Expenses
+ Cost of Materials Consumed	35.7	39.2	33.5	42.7	35.0	39.4	32.7	28.4	39.8	44.7	35.9	40.1
+ Purchases of Stock-in-Trade	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-13.7
+ Changes in Inventories	-3.5	-7.9	10.3	0.6	0.8	-3.8	6.6	6.7	-8.8	-1.1	-5.0	0.0
+ Employee Benefit Expense	12.3	12.6	12.7	14.4	14.1	14.6	16.5	16.3	16.2	16.7	16.2	17.5
+ Finance Costs	2.8	2.3	2.8	2.4	2.1	2.1	2.0	1.9	1.6	1.5	1.4	1.9
+ Depreciation & Amortisation	3.7	3.7	3.8	3.7	3.8	3.8	3.8	3.8	3.9	3.9	3.8	4.2
+ Other Expenses	16.9	18.9	22.1	18.6	20.0	21.6	25.8	19.4	20.6	20.4	23.9	19.8
Total Expenses	67.9	68.8	85.3	82.3	75.8	77.7	87.5	76.5	73.3	86.2	76.2	70.0
EBITDA	7.9	9.3	11.4	16.3	8.6	12.8	7.4	11.7	13.6	14.0	4.2	9.1
EBIT	4.1	5.6	7.6	12.6	4.8	9.0	3.6	7.9	9.7	10.1	0.3	4.9
Profit
PBT before Exceptional Items	1.7	3.8	7.1	10.6	4.7	6.9	3.9	7.0	8.5	8.8	0.9	3.4
Pretax Income	1.7	3.8	7.1	10.6	4.7	6.9	3.9	7.0	8.5	8.8	0.9	3.4
+ Current Tax	1.4	1.5	0.8	3.1	2.4	2.3	1.0	2.4	2.0	2.0	-1.0	1.6
+ Deferred Tax	0.7	-1.8	-0.1	0.4	-1.0	-0.2	-0.6	0.2	0.1	0.1	1.6	-0.0
Tax Expense	2.1	-0.3	0.6	3.5	1.4	2.1	0.4	2.6	2.1	2.1	0.6	1.6
Net Income	-0.4	4.1	6.5	7.1	3.3	4.9	3.5	4.4	6.4	6.6	0.3	1.8
+ Net Income — Continuing Ops	-0.4	4.1	6.5	7.1	3.3	4.9	3.5	4.4	6.4	6.6	0.3	1.8
+ Other Comprehensive Income	0.0	0.0	-0.5	-0.1	-0.1	-0.1	0.5	0.0	0.0	0.0	0.0	0.0
Total Comprehensive Income	-0.4	4.1	6.0	7.0	3.2	4.7	4.0	4.4	6.5	6.7	0.4	1.9
Net Income to Common	0.7	4.3	5.9	7.0	4.7	5.5	3.0	4.2	6.1	6.6	0.4	2.6
Minority Interest	-1.1	-0.2	0.6	0.1	-1.4	-0.6	0.5	0.2	0.3	0.0	-0.1	-0.8
Per Share
Basic EPS	2.20	14.24	19.53	23.15	15.46	18.08	9.83	13.75	20.19	21.89	1.44	8.75
Diluted EPS	2.20	14.24	19.53	23.15	15.46	18.08	9.83	13.75	20.19	21.89	1.44	8.75
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	0.5	0.0	0.0	0.0	0.0	0.0
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-0.8	-0.0	-0.1	-0.1	-0.1	-0.1
+ Tax on Items NOT to be Reclassified — alt tag	-0.0	-0.0	0.7	0.2	0.2	0.2	—	—	—	—	—	—
+ Tax on Items to be Reclassified	—	—	—	—	—	—	0.2	0.0	0.0	0.0	0.0	0.0
+ Tax on Items to be Reclassified — alt tag	0.0	0.0	-0.2	-0.1	-0.1	-0.1	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	0.7	4.3	5.4	6.9	4.5	5.3	3.5	4.2	6.1	6.6	0.5	2.7
Comprehensive Income — Non-controlling Interests	-1.1	-0.2	0.6	0.1	-1.4	-0.6	0.6	0.2	0.3	0.0	-0.1	-0.8
Per Share — as-filed variants
Basic EPS — Continuing Operations	2.20	14.24	19.53	23.15	15.46	18.08	9.83	13.75	20.19	21.89	1.44	8.75
Diluted EPS — Continuing Operations	2.20	14.24	19.53	23.15	15.46	18.08	9.83	13.75	20.19	21.89	1.44	8.75
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	37.0	40.8	46.2	49.2	42.7	49.0	49.7	47.4	50.3	51.2	44.3	46.5
Gross Margin %	53.43	56.58	51.34	53.20	54.40	57.92	55.82	57.41	61.88	53.98	58.90	63.73
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	1.7	3.8	7.1	10.6	4.7	6.9	3.9	7.0	8.5	8.8	0.9	3.4
Net Income Adj (tax-effected)	-0.4	4.1	6.5	7.1	3.3	4.9	3.5	4.4	6.4	6.6	0.3	1.8
EPS Adj	2.20	14.24	19.53	23.15	15.46	18.08	9.83	13.75	20.19	21.89	1.44	8.75
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

HALEOS LABS quarterly results

HALEOS LABS (NSE: HALEOSLABS) has not yet announced the date of its Q2 FY27 results (July–September 2026); they are due by 14 November 2026 under SEBI's 45-day rule. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit attributable to shareholders was ₹2.6 crore, down 36.3% from ₹4.2 crore in Q1 FY26 and up 507.4% from ₹44 lakh in Q4 FY26. Revenue from operations was ₹72.9 crore, down 11.6% year on year and down 2.9% from the previous quarter.

Q2 FY26 results (a year earlier): 10 November 2025
Q1 FY27 results (the latest): 5 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results due by: 14 November 202645 days after the quarter (SEBI)
Q1 FY27 net profit: ₹2.6 Cr−36.3% vs Q1 FY26+507.4% vs Q4 FY26
Q1 FY27 revenue: ₹72.9 Cr−11.6% vs Q1 FY26−2.9% vs Q4 FY26
Q1 FY27 operating margin: 6.7%−2.9 pts vs Q1 FY26+6.3 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹6.1 CrRevenue ₹81.4 Cr
Q1 FY27 EPS (basic): ₹8.75

Questions

When will HALEOS LABS announce its Q2 FY27 results?

The date is not announced yet. Results for July–September 2026 are due by 14 November 2026 (45 days after the quarter, SEBI Regulation 33). Last year it reported Q2 FY26 on 10 November 2025.

What were HALEOS LABS's Q1 FY27 results?

Consolidated net profit attributable to shareholders was ₹2.6 crore, down 36.3% from ₹4.2 crore in Q1 FY26 and up 507.4% from ₹44 lakh in Q4 FY26. Revenue from operations was ₹72.9 crore, down 11.6% year on year and down 2.9% from the previous quarter.

What was HALEOS LABS's net profit in FY26?

Consolidated net profit attributable to shareholders was ₹17.3 crore in FY26 (April 2025–March 2026), down 13.9% from ₹20.1 crore in FY25. It was ₹9.1 crore in FY24 and ₹11.5 crore in FY23: up 51.0% over three years, 14.7% a year on average.

What will HALEOS LABS's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit attributable to shareholders was ₹6.1 crore and revenue from operations ₹81.4 crore. The latest quarter, Q1 FY27, had a net profit of ₹2.6 crore and revenue of ₹72.9 crore.

How has HALEOS LABS's profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹6.1 crore in Q2 FY26, ₹6.6 crore in Q3 FY26, ₹44 lakh in Q4 FY26 and ₹2.6 crore in Q1 FY27. That is ₹15.8 crore over the four quarters, down 8.5% from ₹17.3 crore in the four quarters before. Revenue from operations: ₹81.4 crore, ₹94.8 crore, ₹75.1 crore and ₹72.9 crore.

What was HALEOS LABS's revenue in FY26?

Revenue from operations was ₹334 crore in FY26 (April 2025–March 2026), down 3.2% from ₹345 crore in FY25. It was ₹306 crore in FY24 and ₹316 crore in FY23: up 5.8% over three years, 1.9% a year on average.

Where do these HALEOS LABS figures come from?

From HALEOS LABS's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.